TY  - JOUR
AU  - Escalera, Carlos Rodríguez
AU  - Guisado, Ángela María Zurita
AU  - Mateo, Francisco Javier
AU  - Bahamontes-Rosa, Noemí
AU  - Villanueva, María Jesús García
PY  - 2022
DO  - 10.1007/s10067-022-06287-9
UR  - http://hdl.handle.net/10668/20374
T2  - Clinical rheumatology
AB  - Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical...
LA  - en
KW  - B-cell-targeted therapy
KW  - Belimumab
KW  - Real-life experience
KW  - Real-world data
KW  - Steroid sparing
KW  - Systemic lupus erythematosus
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - Biological Products
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Lupus Erythematosus, Systemic
KW  - Male
KW  - Spain
KW  - Treatment Outcome
TI  - Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.
TY  - research article
VL  - 41
ER  -